Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau

Kentaro Tanemura, Takumi Akagi, Miyuki Murayama, Naomi Kikuchi, Ohoshi Murayama, Tsutomu Hashikawa, Yuji Yoshiike, Jung Mi Park, Keiko Matsuda, Shinobu Nakao, Xiaoyan Sun, Shinji Sato, Haruyasu Yamaguchi, Akihiko Takashima

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a β-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.

Original languageEnglish (US)
Pages (from-to)1036-1045
Number of pages10
JournalNeurobiology of Disease
Volume8
Issue number6
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Neurofibrillary Tangles
Neurodegenerative Diseases
Transgenic Mice
Frontotemporal Dementia
Valine
Parkinsonian Disorders
Methionine
Alzheimer Disease
Mutation
Pharmaceutical Preparations
Genes
Therapeutics

ASJC Scopus subject areas

  • Neurology

Cite this

Tanemura, K., Akagi, T., Murayama, M., Kikuchi, N., Murayama, O., Hashikawa, T., ... Takashima, A. (2001). Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiology of Disease, 8(6), 1036-1045. https://doi.org/10.1006/nbdi.2001.0439

Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. / Tanemura, Kentaro; Akagi, Takumi; Murayama, Miyuki; Kikuchi, Naomi; Murayama, Ohoshi; Hashikawa, Tsutomu; Yoshiike, Yuji; Park, Jung Mi; Matsuda, Keiko; Nakao, Shinobu; Sun, Xiaoyan; Sato, Shinji; Yamaguchi, Haruyasu; Takashima, Akihiko.

In: Neurobiology of Disease, Vol. 8, No. 6, 2001, p. 1036-1045.

Research output: Contribution to journalArticle

Tanemura, K, Akagi, T, Murayama, M, Kikuchi, N, Murayama, O, Hashikawa, T, Yoshiike, Y, Park, JM, Matsuda, K, Nakao, S, Sun, X, Sato, S, Yamaguchi, H & Takashima, A 2001, 'Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau', Neurobiology of Disease, vol. 8, no. 6, pp. 1036-1045. https://doi.org/10.1006/nbdi.2001.0439
Tanemura K, Akagi T, Murayama M, Kikuchi N, Murayama O, Hashikawa T et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiology of Disease. 2001;8(6):1036-1045. https://doi.org/10.1006/nbdi.2001.0439
Tanemura, Kentaro ; Akagi, Takumi ; Murayama, Miyuki ; Kikuchi, Naomi ; Murayama, Ohoshi ; Hashikawa, Tsutomu ; Yoshiike, Yuji ; Park, Jung Mi ; Matsuda, Keiko ; Nakao, Shinobu ; Sun, Xiaoyan ; Sato, Shinji ; Yamaguchi, Haruyasu ; Takashima, Akihiko. / Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. In: Neurobiology of Disease. 2001 ; Vol. 8, No. 6. pp. 1036-1045.
@article{e8353e5448b7452e87b5e807ca1f3833,
title = "Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau",
abstract = "Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a β-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.",
author = "Kentaro Tanemura and Takumi Akagi and Miyuki Murayama and Naomi Kikuchi and Ohoshi Murayama and Tsutomu Hashikawa and Yuji Yoshiike and Park, {Jung Mi} and Keiko Matsuda and Shinobu Nakao and Xiaoyan Sun and Shinji Sato and Haruyasu Yamaguchi and Akihiko Takashima",
year = "2001",
doi = "10.1006/nbdi.2001.0439",
language = "English (US)",
volume = "8",
pages = "1036--1045",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "6",

}

TY - JOUR

T1 - Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau

AU - Tanemura, Kentaro

AU - Akagi, Takumi

AU - Murayama, Miyuki

AU - Kikuchi, Naomi

AU - Murayama, Ohoshi

AU - Hashikawa, Tsutomu

AU - Yoshiike, Yuji

AU - Park, Jung Mi

AU - Matsuda, Keiko

AU - Nakao, Shinobu

AU - Sun, Xiaoyan

AU - Sato, Shinji

AU - Yamaguchi, Haruyasu

AU - Takashima, Akihiko

PY - 2001

Y1 - 2001

N2 - Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a β-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.

AB - Formation of neurofibrillary tangles (NFTs) is the most common feature in several neurodegenerative diseases, including Alzheimer's disease (AD). Here we report the formation of filamentous tau aggregations having a β-sheet structure in transgenic mice expressing mutant human tau. These mice contain a tau gene with a mutation of the frontotemporal dementia parkinsonism (FTDP-17) type, in which valine is substituted with methionine residue 337. The aggregation of tau in these transgenic mice satisfies all histological criteria used to identify NFTs common to human neurodegenerative diseases. These mice, therefore, provide a preclinical model for the testing of therapeutic drugs for the treatment of neurodegenerative disorders that exhibit NFTs.

UR - http://www.scopus.com/inward/record.url?scp=0035664048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035664048&partnerID=8YFLogxK

U2 - 10.1006/nbdi.2001.0439

DO - 10.1006/nbdi.2001.0439

M3 - Article

VL - 8

SP - 1036

EP - 1045

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 6

ER -